Different types of contrast agents used in MRI scans have been discovered to lead to the development of Nephrogenic Systemic Fibrosis in certain instances. These contast agents include Omniscan, ProHance, OptiMARK, Magnevist, and Multihance.

Omniscan was introduced in 1988 by GE Healthcare. The gadodiamide injection, which in unsafe for patients with impaired kidney function, has led to the majority of NSF diagnosis. ProHance is a gadoteridol injection which is most commonly used to detect tumors and other medical issues in the central nervous system. For scans of the brain, liver, and spine, the gadoversetamide injection OptiMARK is normally used. The gadobenate dimeglumine and gadopentetate dimeglumine injections of Multihance and Magnevist have also been linked t NSF.

Although each of these gadolinium-based injections have passed FDA examination, MRIs using these contrast agents have resulted in symptoms of skin tightening, muscle weakness, the stiffening of joints, and kidney problems.

If you have developed NSF after being administered a gadolinium-based contrast agent, please contact the NSF attorneys of Williams Kherkher by calling 800-761-3187 today.